StockData
Jupiter Neurosciences, Inc. logo

Jupiter Neurosciences, Inc. (JUNS) stock

JUNSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$1.52+0.00 (0.00%)

Close on Nov 18, 2026Market cap $1.17MP/E –Yield –

Jupiter Neurosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Jupiter Neurosciences's operating income for the twelve months ending Jun 30, 2026 was -$9.81M. For fiscal 2025 it was -$8.91M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.91M–
FY2024Dec 31, 2024-$3.09M–
FY2023Dec 31, 2023-$3.87M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.74M–
Q1 FY2026Mar 31, 2026-$1.96M–
Q4 FY2025Dec 31, 2025-$2.81M–
Q3 FY2025Sep 30, 2025-$2.30M–
Q2 FY2025Jun 30, 2025-$2.26M–
Q1 FY2025Mar 31, 2025-$1.54M–
Q4 FY2024Dec 31, 2024-$1.46M–
Q3 FY2024Sep 30, 2024-$493.55K–
Q2 FY2024Jun 30, 2024-$557.08K–
Q1 FY2024Mar 31, 2024-$570.70K–
Q4 FY2023Dec 31, 2023-$535.64K–
Q3 FY2023Sep 30, 2023-$1.44M–

More Jupiter Neurosciences figures

See a number that looks wrong?